Valganciclovir

6 trials 2 recruiting JAnti-infectives

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

2 Completed trials

6 Sponsors

6 Countries

Phase III

Phase II

Phase IV

Phase III: 3 Phase II: 2 Phase IV: 1

Indications tested

Cytomegalovirus infection 1 Glioblastoma multiforme 1 Epstein-Barr virus associated lymphoma 1

Sponsors using this IMP

Assistance Publique Hopitaux De Paris 1 Centre Hospitalier Universitaire Rouen 1 Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon 1 Hospital Universitario La Paz 1 Karolinska Institutet 1 Viracta Therapeutics Inc. 1

All trials

6 total

A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients Pending

2023-504846-73-01 Phase II 2 countries Karolinska Institutet
Effectiveness of a preventive strategy for cytomegalovirus infection guided differently from a universal prophylactic strategy in kidney tra… Pending

2024-515925-27-00 Phase III 1 country Centre Hospitalier Universitaire Rouen
Use of tacrolimus and MTOR inhibitors with anticipatory therapy vs. tacrolimus and mycophenolic acid in renal recipients at high risk of pos… Recruiting

2025-520854-12-00 Phase IV 1 country Hospital Universitario La Paz
Letermovir/valganciclovir combination versus valganciclovir monotherapy for treatment of cytomegalovirus (CMV) infections in kidney transpla… Recruiting

2023-506216-40-00 Phase III 1 country Assistance Publique Hopitaux De Paris
CMV preemptive therapy in high-risk immunocompetent major heart surgery patients. A multicenter, double blind, randomized, clinical trial (G… Ended

2022-501429-19-00 Phase III 1 country Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon
An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed… Ended

2024-512717-41-00 Phase II 4 countries Viracta Therapeutics Inc.

Showing 1–6 of 6 trials

← All drugs A–Z